Free Trial
NASDAQ:LGVN

Longeveron Q3 2025 Earnings Report

Longeveron logo
$0.78 -0.05 (-5.96%)
Closing price 04:00 PM Eastern
Extended Trading
$0.79 +0.01 (+1.13%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Longeveron EPS Results

Actual EPS
N/A
Consensus EPS
-$0.26
Beat/Miss
N/A
One Year Ago EPS
N/A

Longeveron Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.29 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Longeveron Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, November 11, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Longeveron Earnings Headlines

Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enforcing that means a $5.39 billion pot must be paid out to everyday Americans. See, virtually every AI model is built off stolen data...tc pixel
Longeveron Appoints Dr. George Paletta to Board
See More Longeveron Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Longeveron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Longeveron and other key companies, straight to your email.

About Longeveron

Longeveron (NASDAQ:LGVN) Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies. Its lead program targets aging frailty, a condition marked by decreased physical function and increased vulnerability in elderly populations. Additional trials are evaluating Lomecel-B in cognitive impairment, acute respiratory distress syndrome (ARDS), bronchopulmonary dysplasia (BPD) in preterm infants and inflammatory complications associated with viral infections. The company leverages collaborations with academic and clinical research centers across North America to advance its programs through Phase 1 and Phase 2 stages.

Headquartered in Miami, Florida, Longeveron conducts its preclinical and clinical operations primarily in the United States and Canada, with plans to expand into other regions as its regulatory strategy evolves. The company maintains partnerships with contract manufacturing organizations to support large-scale production and has engaged regulatory consultants to align its development programs with U.S. Food and Drug Administration guidelines. Longeveron’s approach emphasizes rigorous safety assessment and standardized quality controls to facilitate broader patient access upon potential approval.

Leadership at Longeveron includes Michael L. Bubb, President and Chief Executive Officer, who brings more than two decades of experience in biotechnology and regenerative medicine. Under his direction, the company has established its commercial strategy, overseen its initial public listing on NASDAQ and built a multidisciplinary team covering research, clinical development and regulatory affairs. Longeveron continues to explore strategic collaborations and licensing opportunities to advance its cell therapy platform toward commercial readiness.

View Longeveron Profile

More Earnings Resources from MarketBeat